These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1537 related items for PubMed ID: 11078767

  • 1. Relapses and progression of disability in multiple sclerosis.
    Confavreux C, Vukusic S, Moreau T, Adeleine P.
    N Engl J Med; 2000 Nov 16; 343(20):1430-8. PubMed ID: 11078767
    [Abstract] [Full Text] [Related]

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C, Vukusic S.
    Brain; 2006 Mar 16; 129(Pt 3):606-16. PubMed ID: 16415308
    [Abstract] [Full Text] [Related]

  • 3. Natural history of multiple sclerosis with childhood onset.
    Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C, Adult Neurology Departments KIDMUS Study Group.
    N Engl J Med; 2007 Jun 21; 356(25):2603-13. PubMed ID: 17582070
    [Abstract] [Full Text] [Related]

  • 4. Age at disability milestones in multiple sclerosis.
    Confavreux C, Vukusic S.
    Brain; 2006 Mar 21; 129(Pt 3):595-605. PubMed ID: 16415309
    [Abstract] [Full Text] [Related]

  • 5. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
    Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC.
    Brain; 2006 Mar 21; 129(Pt 3):584-94. PubMed ID: 16401620
    [Abstract] [Full Text] [Related]

  • 6. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H, Yinshan Zhao, Devonshire V.
    Mult Scler; 2008 Apr 21; 14(3):314-24. PubMed ID: 18208898
    [Abstract] [Full Text] [Related]

  • 7. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B, Runmarker B, Winblad S, Ekholm S, Andersen O.
    Brain; 2012 Mar 21; 135(Pt 3):900-11. PubMed ID: 22366800
    [Abstract] [Full Text] [Related]

  • 8. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
    Trojano M, Paolicelli D, Bellacosa A, Cataldo S.
    Neurol Sci; 2003 Dec 21; 24 Suppl 5():S268-70. PubMed ID: 14652786
    [Abstract] [Full Text] [Related]

  • 9. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.
    Neurology; 2007 Oct 09; 69(15):1498-507. PubMed ID: 17699802
    [Abstract] [Full Text] [Related]

  • 10. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.
    Ann Neurol; 2007 Apr 09; 61(4):300-6. PubMed ID: 17444502
    [Abstract] [Full Text] [Related]

  • 11. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 12. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H, Devonshire V.
    Neurology; 2006 Sep 26; 67(6):954-9. PubMed ID: 17000960
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 26; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 17. Natural history of multiple sclerosis: risk factors and prognostic indicators.
    Vukusic S, Confavreux C.
    Curr Opin Neurol; 2007 Jun 04; 20(3):269-74. PubMed ID: 17495619
    [Abstract] [Full Text] [Related]

  • 18. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L, Sylvia Lawry Centre for Multiple Sclerosis Research.
    Neurology; 2006 Sep 12; 67(5):804-8. PubMed ID: 16966541
    [Abstract] [Full Text] [Related]

  • 19. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 12; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

  • 20. Predictors of relapse rate in MS clinical trials.
    Held U, Heigenhauser L, Shang C, Kappos L, Polman C, Sylvia Lawry Centre for MS Research.
    Neurology; 2005 Dec 13; 65(11):1769-73. PubMed ID: 16344520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.